Tildrakizumab tab tom ua lag luam los ntawm Tshav Pharma raws li lub npe lag luam Ilumya, thiab tau txais kev pom zoo los ntawm FDA thaum Lub Peb Hlis 2018 tom qab kev soj ntsuam cov ntaub ntawv los ntawm Phase III multi-centre, randomised, placebo-controlled clinical trials reSURFACE 1 thiab reSURFACE 2. Ob qho kev tshawb fawb tau ua tiav thawj qhov kawg ntawm tsawg kawg yog 75%. ntawm daim tawv nqaij tshem tawm raws li ntsuas los ntawm PASI thiab PGA cov qhab nia. Qhov kev pom zoo los ntawm European Commission thiab TGA, Australia tuaj rau lub Cuaj Hli 2018. Raws li kev soj ntsuam thiab cov nqi siv tau ntawm Ilumya, NICE, UK tau pom zoo siv tildrakizumab hauv 2019 rau kev kho mob psoriasis hnyav.
Plaque psoriasis yog tus kab mob autoimmune inflammatory uas ua rau ze li ntawm 125 lab tus tib neeg thoob plaws ntiaj teb. Feem ntau cov tsos mob muaj xws li cov pob liab liab ntawm cov tawv nqaij, nrog rau lub hauv caug, lub luj tshib, tawv taub hau lossis sab nraub qaum, uas tau mob thiab khaus thiab mob. 80% ntawm cov neeg uas kis tus kab mob no muaj cov tsos mob me me mus rau nruab nrab thaum 20% muaj cov kab mob hnyav uas cov plaques tawg ua rau los ntshav thiab tsis xis nyob ntxiv. Psoriasis muaj kev cuam tshuam tseem ceeb hauv kev sib raug zoo thiab nyiaj txiag rau cov neeg mob uas muaj tus kab mob. Lub neej zoo raug cuam tshuam loj heev vim tus neeg mob muaj kev nyuaj siab thiab kev xav tua tus kheej vim yog 'ib txwm' cov neeg tswj hwm kev sib raug zoo ntawm cov neeg mob ua rau lawv txaj muag thiab ua rau lawv muaj kev ntxhov siab ntxiv.
Ntau yam kev kho mob muaj rau psoriasis nyob ntawm qhov mob hnyav. Nws muaj cov tshuaj pleev ib ce siv cov tshuaj pleev rau ntawm daim tawv nqaij, phototherapy, nyob rau hauv uas cov tawv nqaij raug UV teeb thiab cov tshuaj uas muaj xws li cov tshuaj lom neeg thiab cov khoom siv lom neeg xws li tshuaj tiv thaiv kab mob.
Cov kev kho mob lom hauv vogue rau psoriasis muaj cov tshuaj tiv thaiv xws li etanercept, adalimumab, infliximab, ustekinumab thiab tildrakizumab npe ob peb. Cov tshuaj tiv thaiv no ua los ntawm kev txo qhov mob los ntawm kev tsom mus rau lub hlwb overactive ntawm lub cev tiv thaiv kab mob. Kev kho mob lom neeg feem ntau yog siv rau qhov mob hnyav ntawm psoriasis thaum cov neeg mob tsis teb rau lwm yam kev kho mob uas tau hais los saum toj no.
Ntawm cov chaw lom neeg siv rau kev kho mob psoriasis, tildrakizumab zoo li yog qhov zoo tshaj plaws ntawm kev txo cov tsos mob thiab nws cov nqi. Kev sim tshuaj ntsuam xyuas tau pom tias tildrakizumab txhim kho cov quav hniav loj psoriasis piv nrog cov placebo lossis etanercept nrog kev txhim kho pom tau pom ntawm 28 lub lis piam. Ntxiv mus, tildrakizumab zoo nkaus li zoo li adalimumab thiab ustekinumab. Nrog rau cov nqi, tildrakizumand yog 18% tus nqi ntau dua li adalimumab nyob rau ib hlis ua rau txo nqi tseem ceeb tshaj li tsib xyoos.
Tildrakizumab tab tom ua lag luam los ntawm Tshav Pharms nyob rau hauv lub npe lag luam Ilumya, thiab tau txais kev pom zoo los ntawm FDA thaum Lub Peb Hlis 2018 tom qab kev tshuaj xyuas cov ntaub ntawv los ntawm Phase III multi-centre, randomised, placebo-controlled clinical trials reSURFACE 1 thiab reSURFACE 2. Ob qho kev tshawb fawb tau ua tiav thawj qhov kawg ntawm yam tsawg kawg 75% ntawm daim tawv nqaij clearance raws li ntsuas. los ntawm PASI thiab PGA cov qhab nia. Qhov kev pom zoo los ntawm European Commission thiab TGA, Australia tuaj rau lub Cuaj Hli 2018. Raws li kev soj ntsuam thiab cov nqi siv tau ntawm Ilumya, NICE, UK tau pom zoo siv tildrakizumab hauv 2019 rau kev kho mob psoriasis hnyav.
***
Lus raug kaw.